title: Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
authors.forename: Akiko
authors.initials: A
authors.lastname: Inoue
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kawakami
authors.forename: Kimitaka
authors.initials: K
authors.lastname: Takitani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamai
mesh_terms: D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D004334:Drug Administration Schedule; D000079982:Gemtuzumab; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D001152:Arsenicals; D001565:Benzoates; D010087:Oxides; D013764:Tetrahydronaphthalenes; C061133:tamibarotene; D014212:Tretinoin; D000079982:Gemtuzumab; D000077237:Arsenic Trioxide